BACKGROUND: Pendrin is a transport protein exchanging chloride for other anions, such as iodide in the thyroid gland or bicarbonate in the inner ear. Mutations in the SLC26A4 gene encoding for pendrin are responsible for both syndromic (Pendred syndrome) and non-syndromic (non-syndromic enlarged vestibular aqueduct, EVA) hearing loss. Besides clinical and radiological assessments, molecular and functional studies are essential for the correct diagnosis of Pendred syndrome and non-syndromic EVA. While a broad spectrum of mutations found in the Caucasian population has been functionally characterized, little is known about mutations specifically occurring in the populations of the Middle East. Here we show the characterization of the ion transport activity of three pendrin mutations previously found in deaf patients with EVA in the Israeli Jewish and Palestinian Arab populations, i.e. V239D, G334V X335 and I487Y FSX39. METHODS: Wild type and mutated pendrin allelic variants were functionally characterized in a heterologous over-expression system. The Cl(-)/I(-) and Cl(-)/OH(-) exchange activities were assessed by fluorometric methods suitable for measuring iodide fluxes and the intracellular pH. RESULTS: Both the Cl(-)/I(-) and the Cl(-)/OH(-) exchange activities of pendrin V239D, G334V X335 and I487Y FSX39 were significantly reduced with respect to the wild type, with V239D displaying a residual iodide transport. CONCLUSION: Functional assays confirmed the diagnosis of non-syndromic EVA due to SLC26A4 mutations performed by radiological and molecular tests in deaf patients belonging to the Israeli Jewish and Palestinian Arab populations. The new finding that the V239D mutation displays residual function suggests that the symptoms caused by this mutation could be ameliorated by a pendrin 'activator', if available.
BACKGROUND:Pendrin is a transport protein exchanging chloride for other anions, such as iodide in the thyroid gland or bicarbonate in the inner ear. Mutations in the SLC26A4 gene encoding for pendrin are responsible for both syndromic (Pendred syndrome) and non-syndromic (non-syndromic enlarged vestibular aqueduct, EVA) hearing loss. Besides clinical and radiological assessments, molecular and functional studies are essential for the correct diagnosis of Pendred syndrome and non-syndromic EVA. While a broad spectrum of mutations found in the Caucasian population has been functionally characterized, little is known about mutations specifically occurring in the populations of the Middle East. Here we show the characterization of the ion transport activity of three pendrin mutations previously found in deaf patients with EVA in the Israeli Jewish and Palestinian Arab populations, i.e. V239D, G334V X335 and I487Y FSX39. METHODS: Wild type and mutated pendrin allelic variants were functionally characterized in a heterologous over-expression system. The Cl(-)/I(-) and Cl(-)/OH(-) exchange activities were assessed by fluorometric methods suitable for measuring iodide fluxes and the intracellular pH. RESULTS: Both the Cl(-)/I(-) and the Cl(-)/OH(-) exchange activities of pendrinV239D, G334V X335 and I487Y FSX39 were significantly reduced with respect to the wild type, with V239D displaying a residual iodide transport. CONCLUSION: Functional assays confirmed the diagnosis of non-syndromic EVA due to SLC26A4 mutations performed by radiological and molecular tests in deaf patients belonging to the Israeli Jewish and Palestinian Arab populations. The new finding that the V239D mutation displays residual function suggests that the symptoms caused by this mutation could be ameliorated by a pendrin 'activator', if available.
Authors: Pnina Rotman-Pikielny; Koret Hirschberg; Padma Maruvada; Koichi Suzuki; Ines E Royaux; Eric D Green; Leonard D Kohn; Jennifer Lippincott-Schwartz; Paul M Yen Journal: Hum Mol Genet Date: 2002-10-01 Impact factor: 6.150
Authors: Susan M Wall; Kathryn A Hassell; Ines E Royaux; Eric D Green; Judy Y Chang; Gregory L Shipley; Jill W Verlander Journal: Am J Physiol Renal Physiol Date: 2002-08-27
Authors: L A Everett; B Glaser; J C Beck; J R Idol; A Buchs; M Heyman; F Adawi; E Hazani; E Nassir; A D Baxevanis; V C Sheffield; E D Green Journal: Nat Genet Date: 1997-12 Impact factor: 38.330
Authors: Hongwei Dou; Jie Xu; Zhaohui Wang; Annabel N Smith; Manoocher Soleimani; Fiona E Karet; John H Greinwald; Daniel Choo Journal: J Histochem Cytochem Date: 2004-10 Impact factor: 2.479
Authors: David P DiCiommo; Allison Duckett; Irina Burcescu; Rod Bremner; Brenda L Gallie Journal: Invest Ophthalmol Vis Sci Date: 2004-09 Impact factor: 4.799
Authors: Mary P Gillam; Aniket R Sidhaye; Eun Jig Lee; Jonas Rutishauser; Catherine Waeber Stephan; Peter Kopp Journal: J Biol Chem Date: 2004-01-08 Impact factor: 5.157
Authors: Ines E Royaux; Inna A Belyantseva; Tao Wu; Bechara Kachar; Lorraine A Everett; Daniel C Marcus; Eric D Green Journal: J Assoc Res Otolaryngol Date: 2003-09
Authors: Andrea M Oza; Marina T DiStefano; Sarah E Hemphill; Brandon J Cushman; Andrew R Grant; Rebecca K Siegert; Jun Shen; Alex Chapin; Nicole J Boczek; Lisa A Schimmenti; Jaclyn B Murry; Linda Hasadsri; Kiyomitsu Nara; Margaret Kenna; Kevin T Booth; Hela Azaiez; Andrew Griffith; Karen B Avraham; Hannie Kremer; Heidi L Rehm; Sami S Amr; Ahmad N Abou Tayoun Journal: Hum Mutat Date: 2018-11 Impact factor: 4.878
Authors: Amal Abu Rayyan; Lara Kamal; Silvia Casadei; Zippora Brownstein; Fouad Zahdeh; Hashem Shahin; Christina Canavati; Dima Dweik; Tamara Jaraysa; Grace Rabie; Ryan J Carlson; Suleyman Gulsuner; Ming K Lee; Karen B Avraham; Tom Walsh; Mary-Claire King; Moien N Kanaan Journal: Proc Natl Acad Sci U S A Date: 2020-08-03 Impact factor: 11.205
Authors: Yongyi Yuan; Weiwei Guo; Jie Tang; Guozheng Zhang; Guojian Wang; Mingyu Han; Xun Zhang; Shiming Yang; David Z Z He; Pu Dai Journal: PLoS One Date: 2012-11-21 Impact factor: 3.240
Authors: Dona M Kanavy; Shannon M McNulty; Meera K Jairath; Sarah E Brnich; Chris Bizon; Bradford C Powell; Jonathan S Berg Journal: Genome Med Date: 2019-11-29 Impact factor: 11.117